CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC).

Thoracic Cancer
Qiong QinDiansheng Zhong

Abstract

The third-generation EGFR-TKI, represented by osimertinib, has been widely used in clinical practice; however, resistance eventually emerges. At present, it remains unclear whether an abnormal cell cycle is involved in acquired resistance, and whether the combination of palbociclib (CDK4/6 inhibitor) and osimertinib can overcome the third-generation TKI resistance. We established osimertinib-resistant cells (H1975 OR) derived from EGFR-mutant NSCLC cells H1975. Drug effects on cells were assessed with Cell Counting Kit-8 (CCK8). Protein alterations were detected with western blot analysis. RT-PCR was used to evaluate the differences of gene mRNA. Cell cycle distribution of H1975 S and H1975 OR cells was compared using flow cytometry. Compared with H1975, the sensitivity of H1975OR to the CDK4/6 inhibitor was increased and the proportion of cells in G1 phase was decreased. The mRNA level of CDK4, CDK 6 and the protein level of CDK4, pRB were increased in H1975OR. In the H1975OR cells, palbociclib significantly increased the proportion of G1 phase cells. The combination of osimertinib and palbociclib synergistically decreased the survival of H1975OR by cell cycle arrest. Combined treatment was found to inhibit the initial phospho...Continue Reading

References

Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Jan 22, 2009·Molecular BioSystems·Manfred T ReetzJoaquin Sanchis
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Nov 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keith T FlahertyGary K Schwartz
Jul 4, 2012·Nature Genetics·Zhenfeng ZhangTrever G Bivona
Mar 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helena A YuGregory J Riely
Dec 15, 2015·Cancer Discovery·Charles J SherrGeoffrey I Shapiro
Jan 6, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhen TaoBo Lu
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He
Mar 6, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Frank C DetterbeckUNKNOWN Multiple Pulmonary Sites Workgroup
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Dec 14, 2016·The New England Journal of Medicine·Tony S MokUNKNOWN AURA3 Investigators
Oct 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzAngelo Di Leo
Nov 28, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hai-Yan TuYi-Long Wu
Jan 18, 2019·Nature Communications·Hirokazu TaniguchiSeiji Yano
Oct 1, 2019·British Journal of Cancer·Alessandro LeonettiMarcello Tiseo
Nov 22, 2019·The New England Journal of Medicine·Suresh S RamalingamUNKNOWN FLAURA Investigators

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

FLAURA
AURA3
GraphPad
ModFit LT
GraphPad Prism

Related Concepts

Related Feeds

Cell Cycle Pathways

Cell cycle is a complex process regulated by several signal transduction pathways and enzymes. Here is the latest research on regulation of cell cycle and cell cycle pathways.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.